Research News

No increased heart failure risk is reported with DPP-4 inhibitors

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2363 (Published 26 April 2016) Cite this as: BMJ 2016;353:i2363
  1. Jacqui Wise
  1. London

The risk of heart failure is no higher in patients taking the dipeptidyl peptidase-4 inhibitors (DPP-4) saxagliptin or sitagliptin than in those taking other drugs commonly prescribed for type 2 diabetes, researchers have found.1

A large retrospective cohort study published in the Annals of Internal Medicine compared new users of DPP-4 inhibitors with new users of second generation sulphonylureas, pioglitazone, or …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe